financetom
Business
financetom
/
Business
/
Ford CFO Transition Plan Aids Efforts to Build Talent, Shift Culture, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ford CFO Transition Plan Aids Efforts to Build Talent, Shift Culture, UBS Says
May 13, 2024 1:23 PM

04:06 PM EDT, 05/13/2024 (MT Newswires) -- Ford Motor's ( F ) news on Friday that it will transition Chief Financial Officer John Lawler to a vice chair role supports management's efforts to build talent and change culture, UBS Securities said.

Ford said Friday that it hired former Lucid Motors (LCID) CFO Sherry House to eventually replace Lawler as the finance chief early next year. The CFO succession came as a surprise to UBS analyst Joseph Spak and likely to investors, he said in a note emailed Monday reiterating a neutral rating and a $14 price target on the stock.

"In our view, Lawler was a steady hand and liked by investors, so the change will need to be digested," he wrote. Shares of Ford closed 2.8% higher on Monday.

Lawler will take on broader responsibilities within strategy, global partnerships and lobbying, leading areas that Ford said are "critical to its long-term success."

Ford used the vice chair role before, including most recently between May 2021 and December 2022.

Some investors already have experience with House from her time at Lucid but an adjustment period will be needed, according to UBS. The optics are challenging given her background in electric vehicles at a time when investors like hearing about internal combustion engines amid the overall deceleration in EV demand. Ford may also field skeptics who know that it has had troubles hiring outside talent to the CFO role in the past, the brokerage said.

"We do note that this current plan looks to have a longer transition period than prior efforts," Spak said.

On an earnings conference call with analysts in February, Chief Executive Jim Farley said the company's performance management capabilities are crucial to bringing in and retaining the best talent while aligning incentives with shareholder value creation, according to a Capital IQ transcript.

These management moves are "part of Ford's initiative to build talent, capabilities, change their culture and develop succession planning," Spak said.

Price: 12.36, Change: +0.37, Percent Change: +3.04

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Eli Lilly, Novo Nordisk, Hims & Hers Health Shares Move Lower After Trump Calls Out 'Fat-Loss Drugs'
Eli Lilly, Novo Nordisk, Hims & Hers Health Shares Move Lower After Trump Calls Out 'Fat-Loss Drugs'
Oct 16, 2025
Shares of Eli Lilly And Co ( LLY ) and Novo Nordisk A/S ( NVO ) are moving lower in Thursday’s after-hours session after President Donald Trump indicated that weight-loss drugs are going to come down in price. • LLY stock is showing weakness. Get the complete picture here. What To Know: In a press conference from the White House...
Uipath Insider Sold Shares Worth $2,112,412, According to a Recent SEC Filing
Uipath Insider Sold Shares Worth $2,112,412, According to a Recent SEC Filing
Oct 16, 2025
05:27 PM EDT, 10/16/2025 (MT Newswires) -- Daniel Dines, 10% Owner, Director, CEO and Chairman, on October 16, 2025, sold 122,734 shares in Uipath ( PATH ) for $2,112,412. Following the Form 4 filing with the SEC, Dines has control over a total of 30,158,585 Class A common shares of the company, with 29,918,585 shares held directly and 240,000 controlled...
Trump says price of Ozempic will be lowered
Trump says price of Ozempic will be lowered
Oct 16, 2025
WASHINGTON (Reuters) -U.S. President Donald Trump said on Thursday that the price of Novo Nordisk's best-selling weight-loss drug would be lowered and that negotiations over price changes would be swift. Trump made the comments during a White House event on fertility treatments and drug pricing. He was asked by reporters to identify the name of a drug that he earlier...
WaFd Fiscal Q4 Non-GAAP Earnings Rise, Revenue Falls
WaFd Fiscal Q4 Non-GAAP Earnings Rise, Revenue Falls
Oct 16, 2025
05:25 PM EDT, 10/16/2025 (MT Newswires) -- WaFd ( WAFD ) reported fiscal Q4 non-GAAP earnings late Thursday of $0.72 per diluted share, up from $0.68 a year earlier. Four analysts polled by FactSet expected $0.77. Revenue for the quarter ended Sept. 30, expressed as the sum of net interest income and total noninterest income, was $188.3 million, down from...
Copyright 2023-2026 - www.financetom.com All Rights Reserved